آقانژاد، ايوب نويسنده Department of Nuclear Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences Aghanejad, Ayuob , جليليان ، اميررضا نويسنده Jalilian, A.R , بهرامي ساماني، علي نويسنده , , بيگي، داوود نويسنده Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran Beiki, Davood , ماس، استفان نويسنده Clinic of Nuclear Medicine, University Medical Centre Mainz, Langenbeckstrasse 1, D-55131 Mainz, Germany Maus, Stephan , خلج ، علي نويسنده ,
Introduction: In continuation of recent development of possible C-X-C chemokine receptor type 4 (CXCR4) imaging
agents, we report the development of a possible CXCR4 targeted therapy agent.
Methods: [153Sm]labeled 1,1?-[1,4-phenylenebis(methylene)] bis-1,4,8,11-tetraazacyclo- tetradecane ([153Sm]-AMD3100)
was prepared using [153Sm]SmCl3 and AMD-3100 for 24h at 50?C in acetate buffer. Stability tests, partition coefficient
determination, toxicity tests and biodistribution studies of the complex in wild-type rats were determined.
Results: The radiolabeled complex was prepared in high radiochemical purity ( > 95%; RTLC and > 99% HPLC) and specific
activity of 278 GBq/mmol and demonstrated significant stability up to 48h at 37 ?C (in presence of human serum). Partition
coefficient determination was calculated Log P= -1.09. Hepatotoxicity experiments demonstrated no distinguishable effect
on hepatic enzymes in 10 days post injection. Initial complex biodistribution data showed significant liver and kidney
accumulation in wild-type rats.
Conclusion: Since lung and spleen are considered as CXCR4 rich organs, the best lung/blood and spleen/blood ratios were
achieved 12 and 7 at 24 h post injection. Further investigations are needed especially on therapeutic properties of this agent.